Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single-ascending and Multiple-dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-AAT02 in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Next Previous
Trial Profile

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single-ascending and Multiple-dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-AAT02 in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALN-AAT02 (Primary)
  • Indications Alpha 1-antitrypsin deficiency; Liver disorders
  • Focus Adverse reactions; First in man
  • Sponsors Alnylam Pharmaceuticals

Most Recent Events

  • 10 Oct 2020 This trial has been completed in United Kingdom (Date of the global end of the trial: 5 June 2020).
  • 15 Sep 2020 Status changed from active, no longer recruiting to discontinued as the sponsor decided not to proceed with Part B for business reasons. .
  • 06 Apr 2020 According to a Dicerna Pharmaceuticals media release, Dicerna will Lead Global Clinical Development and U.S. Commercialization of Alnylams ALN-AAT02 Investigational Therapeutics for the Treatment of Alpha-1 Liver Disease

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top